No serious safety concerns were raised over Merck & Co's experimental pill for ragweed allergies, according to FDA documents Friday, ahead of a meeting next week of outside medical experts who will discuss whether the drug merits approval. The Allergenic Products Advisory Committee will meet on Tuesday to review Ragwitek, a pill placed under the tongue that, if approved, would be an alternative to regular injections administered by doctors for ragweed pollen allergies. At the meeting, the panel will be asked to discuss whether available clinical trial data supports the safety and the efficacy of the product in persons 18 years of age and older and make recommendations to the U.S. Food and Drug Administration.
Help employers find you! Check out all the jobs and post your resume.
